Abbvie announced that it is dropping its triplet therapy for cystic fibrosis (CF) after a disappointing interim analysis in a phase II study. The combination therapy, which added another drug to an experimental 2-drug treatment, failed to improve forced expiratory volume in one second (FEV1), a key metric for CF management. The withdrawal of the trial is another win for Abbvie’s competitor, Vertex.
According to Nicole DeFeudis of Endpoints News, “Now, AbbVie’s Phase II flop has cleared the way for Vertex to maintain its tight grip on the CF market. Trikafta — Vertex’s triplet therapy darling first approved back in 2019 — raked in more than $7.5 billion last year. And the company has its own next-gen therapy in the works, as CEO Reshma Kewalramani aims to stay one step ahead of the competition.”
Click here to read more.
(Source: Endpoints News, April 29th, 2022)